An innovation-driven global pharmaceutical company Glenmark Pharmaceuticals Limited has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin with Pioglitazone. This is the only available brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name ZitaPlusPio which contains Teneligliptin (20 mg) + Pioglitazone (15 mg) to be taken once a day.
Glenmark is the first company in India to market the innovative FDC of Teneligliptin+ Pioglitazone which is approved by the Drug Controller General of India. It will be useful for patients who require treatment to improve glycemic control reducing Insulin Resistance. Type 2 diabetics typically face issues of β cell dysfunction and insulin resistance. The combination has the efficacy to tackle these two most important path physiologies which makes it more effective in managing uncontrolled Type 2 diabetes. It will provide a synergistic approach wherein Teneligliptin will optimally improve β cell sensitivity and Pioglitazone will effectively reduce insulin resistance. According to the International Diabetes Federation, the prevalence of diabetes in India is around 74 million adults which is expected to increase to 125 million by 2045. 77% out of these patients have uncontrolled diabetes.
The Group Vice President & Head of India Formulations at Glenmark Pharmaceuticals Alok Malik said, “We are delighted to introduce this novel ZitaPlusPio which is offering a world-class and affordable treatment option to adult diabetic patients.”
